Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease who are eligible to receive the drug.

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

Results from a phase 3 clinical trial, recently published in The Lancet Oncology, present a significant breakthrough in the ...

Outranked only by skin cancer, prostate cancer is the second most common cancer in men in the U.S. Although one in every ...

Doctor warns men over 50 that common urinary symptoms might signal prostate cancer, urging them to seek medical advice rather ...

Earlier this week, researchers presented data from the OPTIMUM (Optimization of Prostate Biopsy – Micro-Ultrasound Versus MRI ...

Research reveals men skipping prostate cancer screenings are 45% more likely to die from the disease. Evidence from a large European study indicates P ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

The report forecasts global market growth from $116.1 billion in 2024 to $168 billion by 2029 at a CAGR of 7.7%. Highlighting advances in immunothera ...

A global study finds that low milk intake is linked to increased colorectal cancer burden, especially in older adults.

Onconetix (ONCO) announced that new clinical data of Proclarix was presented on March 23, 2025 during the 2025 European ...